David Watson - 21 Jan 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
General Counsel
Signature
/s/ David Watson
Issuer symbol
APLS
Transactions as of
21 Jan 2022
Transactions value $
$0
Form type
4
Filing time
25 Jan 2022, 15:49:41 UTC
Previous filing
10 Feb 2022
Next filing
01 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Award $0 +26,051 +24.23% $0 133,585 21 Jan 2022 Direct F1
holding APLS Common Stock 10,000 21 Jan 2022 See Footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Award $0 +36,951 $0 36,951 21 Jan 2022 Common Stock 36,951 $35.46 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents a restricted stock unit grant made on January 21, 2022 that vests 25% annually in equal installments over four years from the date of grant, subject to continued service.
F2 The securities are held by The Watson Education Trust (the "Trust"), for which the reporting person serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Trust except to the extent of his pecuniary interest therein.
F3 This represents a non-qualified stock option grant made on January 21, 2022 that vests over a four year period with 25% vesting one year from grant date and the remaining 75% vesting in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service.